Skip to main content
Equibles

Matthew

Analyst

Bank of America

Equibles does not estimate personal net worth.

About Matthew

Matthew is recorded as Analyst at Bank of America. Matthew has spoken on 8 earnings calls across 4 companies, most recently for Vir Biotechnology, Inc. on May 6, 2026. Those appearances were for Vir Biotechnology, Inc. (VIR), Krystal Biotech, Inc. (KRYS), Moderna, Inc. (MRNA) and EIDP, Inc. (CTA-PB). The companies whose calls Matthew spoke on are classified in the Healthcare and Basic Materials sectors.

Matthew on recent calls

“I guess two for us on competitive landscapes first for HDV just curious your thoughts on your data that came out recently whether that sort of changes your thoughts on commercial opportunity or competitive landscape and then secondly for EGFR T-cell engagers competitor of yours recently you know discontinued…”
Analyst — Bank of America, Vir Biotechnology, Inc. Q1 FY2026 Earnings Call ·
“Maybe for RCC, can you walk us through what makes you confident Phase 2 could be registrational and what hazard ratio or benefit you think would be compelling?”
Analyst — Bank of America, Moderna, Inc. Q4 FY2025 Earnings Call ·
“You talked openly about, in kind of the initial days of the announcement, that seed would be looking to expand beyond corn and soy. And I know you have the hybrid wheat coming out next year, which is obviously exciting.”
Analyst — Bank of America, Corteva Agriscience 4Q 2025 Earnings ·
“In terms of the 48-week HTV data, can you maybe speak to how meaningful this data is is for physician education ahead of a potential launch and any reason to think that there would be a significant change from week 36 to 48?”
Analyst — Bank of America, Vir Biotechnology, Inc. Q3 FY2025 Earnings Call ·

Affiliation history

  • Bank of America

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity